IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · Real-Time Price · USD
1.290
-0.020 (-1.53%)
Aug 14, 2025, 11:29 AM - Market open
CTI BioPharma Stock Forecast
Stock Price Forecast
The 3 analysts that cover CTI BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $8.67, which forecasts a 572.09% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $12.
Price Target: $8.67 (+572.09%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +210.08% | Aug 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +830.23% | Apr 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +830.23% | Mar 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +830.23% | Nov 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +830.23% | Nov 6, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
19.66M
EPS This Year
-1.34
from -1.45
EPS Next Year
-1.07
from -1.34
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | 44.4M | 136.8M |
| Avg | n/a | 19.7M | 77.4M |
| Low | n/a | 4.6M | 23.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | 595.9% |
| Avg | - | - | 293.7% |
| Low | - | - | 21.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.20 | -0.95 | -0.64 | ||
| Avg | -1.34 | -1.07 | -0.70 | ||
| Low | -1.48 | -1.33 | -0.76 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.